Latest Drugs, Latest Approval in PCSK9 inhibitors

What are PCSK9 inhibitors?

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme that binds to low-density lipoprotein receptors (LDL receptors), which stops LDL being removed from the blood, leading to an increase in blood levels of LDL. The PCSK9 inhibitor blocks the PCSK9 enzyme, resulting in more LDL receptors available to remove LDL from the blood, which produces in a decrease in LDL blood levels.

Name Updated
Repatha prefilled syringe (Evolocumab [ e-voe-lok-ue-mab ]) 15-Aug-2023
Repatha autoinjector (Evolocumab [ e-voe-lok-ue-mab ]) 15-Aug-2023
Evolocumab (Evolocumab) 13-Aug-2023
Alirocumab (Alirocumab) 13-Aug-2023
Repatha sureclick (Evolocumab [ e-voe-lok-ue-mab ]) 14-Jul-2023
Repatha pushtronex (Evolocumab [ e-voe-lok-ue-mab ]) 14-Jul-2023
Repatha (Evolocumab [ e-voe-lok-ue-mab ]) 11-Jul-2023
Praluent (Alirocumab [ al-i-rok-ue-mab ]) 11-Jul-2023